Posts Tagged healthcare
Speedy identification of pathogens: saves lives, reduces cost & lowers antibiotic resistance problem
Posted by Darshana V. Nadkarni, Ph.D. in Biotech - Medical Device - Life Science - Healthcare on September 24, 2019
At a recent Bio2DeviceGroup (www.bio2devicegroup.org) event, Kevin Hacker, CEO of BioAffinity Sciences talked about their new technology that when fully developed will identify pathogens more than 100 times faster than the traditional blood culture and related technologies currently in use.
Every year, in the US, 500 thousand people die due to sepsis related complications. Sepsis is a final common pathway for many infections, particularly when an individual’s immunity is low. Body normally releases chemicals into the bloodstream to fight an infection. When the body’s response to these chemicals is out of balance, it results in Sepsis. That is when body’s immune system launches a massive counter attack that harms body’s own tissues and organs. The triggering changes begin to damage body’s vital organ systems that results in dramatic drop in the blood pressure, ultimately leading to death.
Sepsis and septic shock are more common if the individual is very young or very old, have a compromised immune system, have diabetes or cirrhosis, is already sick and frequently in a hospital intensive care unit, have wounds or injuries or severe burns, have invasive devices inserted into the body, and have previously received antibiotics or corticosteroids. Often people can recover from mild sepsis. However, if the body goes into septic shock, the average mortality rate for septic shock is about 40%. Additionally, an episode of severe sepsis may place a person at higher risk of future infections.
Given that widespread infections can progress to Sepsis and Sepsis shock in a matter of few hours, it is imperative that such infections be treated immediately with antibiotics. When given the right antibiotics, there is often a dramatic improvement and speed of cure.
Problem with speedy identification of pathogens
Given that early treatment of sepsis is associated with vastly improved outcomes, rapid diagnosis is essential. However blood culture work is slow and often takes 1-3 days. The diagnosis of sepsis in critically ill patients, housed in hospitals is also challenging because it can be complicated by the presence of inflammation resulting from other underlying diseases and from prior use of antibiotics, making cultures negative. Most testing is done through mass spectrometry that gives mass to charge ratio of ions. Since culture-dependent diagnosis of infection is slow, sometimes patients are given antibiotics, before the results of the culture are available. Patients are given broad spectrum antibiotics and 40% are not effective. In such instances, antibiotics are withdrawn after one cycle of treatment, when the cause of the illness is found to be something else and this can lead to antibiotic resistance.
Bioaffinity Sciences solution will be able to identify pathogens within 10 minutes, 430 fold faster than blood culture. This is cell affinity based, low cost technology. Pathogens are run through microchannels comprising of a surface- grafted scaffold of reactive polymer onto which affinity molecules (sugars, aptamers, vancomycin, and methicillin) have been bio-conjugated. High capacity of the channels allows low numbers of microbes to be quickly identified. The unknown pathogen’s pattern of binding to the channels is recorded, and this pattern is compared to a library of known pathogens. When a match is made, the identity of the pathogen is reported. In addition to speed, this is also more sensitive in terms of the number of different pathogens detected than blood culture.
Disease burden to the healthcare system in the US due to Sepsis
Sepsis management is a major challenge and results in disproportionately high burden in terms of hospital utilization. The average length of stay for sepsis patients in the US is approximately 75% greater than for other conditions. The cost of sepsis management ranks highest among hospital admissions for all disease states. The cost is estimated to be between $25 billion and $27 billion, and represents 13% of total US hospital costs.
Considering that poor sepsis outcomes are directly tied to the delay in diagnosis and treatment, such a dramatic improvement in speed and accuracy of diagnosis leading to speedy and accurate treatment can not only dramatically improve outcome and quality of patient care but also significantly reduce cost of care for hospitals.
The talk was followed by Q&A.
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship, Biotech - Medical Device - Life Science - Healthcare on January 12, 2018
JPM 2018 and concurrent events just ended with what may be one of its biggest draws. As many as 10,000 people from life science industry and its related sectors are likely to have descended upon the city, during last four days. In addition to JPM event itself, everything health was under review and up for discussion at various conferences including at EBD Group & Demy Colten’s #BiotechShowcase #DigitalMedicine #BTS18 and #WuXiGlobalForum2018 . Networking and deal making continued late in the nights at various receptions held across the city. Receptions by legal firms like #WilsonSonsini #MoFoLLP #ReedSmithLLP attracted some of the biggest crowds.
Overall the tone for 2018, seemed highly optimistic. BiotechShowcase held a media roundup and echoes of optimism were heard from almost all panelists @barbara_ryan12 @TriangleInsight @CarolineYLChen @adamfeuerstein @statnews @SFBIZronleuty @BrittanyMeiling @endpts @juliet_preston @medcitynews @ldtimmerman .
There is a general agreement that the pace of #innovation in biotech greatly accelerated in 2017 and is likely to continue. According to Luke Timmeerman, “sheer velocity of news in healthtech innovation is fascinating”. Transformative therapies across huge and diverse range of diseases are increasingly focusing on cures and going beyond the short term treatment focus. The surge of innovation has been led by focus on oncology although concern was also raised in one of the panels that we still continue to get stymied and realize how friggin smart the disease of cancer is and if we will truly crack the code on cancer in the immediate upcoming years. All signs are however, that next year we may see critical data from some clinical trials in immuno-oncology space that can cause market spikes.
Here are some areas of concern raised in some of the panels. In 2017, a slight dip was observed in the areas of orphan and rare diseases. Also there seemed to be a general consensus that we need smart policies that incentivize new anti microbial drugs and other treatments for infectious diseases. Due to increasing resistance of antibiotics, there is an ongoing and real fear for some of the infectious diseases to turn into pandemics. These are areas that bold entrepreneurs may focus on. Also medical devices continues to remain somewhat underfunded. Discussions around accelerating healthcare costs and drug pricing issues creeped over into many panels. Entrepreneurs with disruptive pricing innovation in product development as well as healthcare can easily have a tremendous leverage. It can’t be overstressed that finding effective pricing solutions holds key to continued and sustainable growth in healthcare sector.
Discussion in one of the panels focused for a few minutes around large investments in life sciences and if that indicated a healthtech bubble that may be due for a crash. Indeed, some experts observed that pace of 2017 is unlikely to continue and there may well be a slight dip in 2018. But overall the consensus seemed to be, that a steep and deep pipeline of innovation in R&D is likely to prevent a crash, and the venture funding blizzard is likely to continue. Overall, the feeling among investors and healthcare experts was that among the industry, there is a strong focus on science and people are pursuing innovation with discipline that will ensure unprecedented mechanisms and novel medicines. All this activity is taking healthcare to a new level of cures and sustainability and stability from temporary treatment focus. Exciting indeed to be living in this era of amazing healthcare innovation.
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship, Biotech - Medical Device - Life Science - Healthcare on December 26, 2017
Biotech Showcase taking place concurrently with the J P Morgan event in San Francisco in January 2018, is an investor and networking conference. Many partnerships and collaborations will be forged with over over 7000 one on one meetings, with opportunities for eager innovators to seek out enthusiastic investors. Besides one on one meetings, general sessions will focus on a number of disease areas that are significantly expected to impact the healthcare arena. More blogs to follow and will highlight focus on new treatment modalities.
A panel led by Jennifer Goldstein from Silicon Valley Bank will focus on body’s largest organ that is often misunderstood and frequently underrated, the skin. Panelists Alan Dunton from Purdue Pharma, David Giljohann from Exicure, Jennifer Good from Trevi Therapeutics, Shelley Harman from Aegle and Mark Wilson from MatriSys will discuss early signs and symptoms on the skin that often signal infectious and internal diseases.
Antimicrobial resistance or (AMR) is increasingly a prominent public health concern and has been highlighted by both WHO and CDC. Since the discovery of first antibiotic penicillin in 1928, more than 100 compounds have been created but no new class has been found. In panel moderated by Bibhash Mukhopadhyay at New Enterprise Associates, leading anti-microbial drug development experts, Alan Carr of Needham, Julia Gregory from Contrafect, Kenneth Hillan from Achaogen, Gregory Mario from Taxis Pharma, John Rex from F2G, and Chris Stevens from Arsanis will discuss the tailwinds and headwinds in this space that is getting a fresh second look from both experts and investors.
Current epidemic of metabolic syndrome will be the focus in a panel moderated by Philip Kenner from ClearView with panelists Deborah Dunsire from DTuit, Tomas Landh from Novo Nordisk, Harith Rajagopalan from Fractyl Labs, and Wendye Robbins from Blade Therapeutics. Having any one of the risk factors like high blood pressure, high blood sugar, obesity, high cholesterol, or high triglycerides can greatly increase health risk. However having a cluster of these conditions together indicate metabolic syndrome and vastly increase health risk. Metabolic syndrome is on the rise, reaching epidemic proportions according to some health experts.
While JPM conference is by invitation only event, registration is open for Biotech Showcase at email@example.com or at https://ebdgroup.knect365.com/biotech-showcase/agenda/1
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship, Biotech - Medical Device - Life Science - Healthcare on April 30, 2015
Are you still playing inside the boundaries of disciplines? Play on the boundaries, instead. There are huge opportunities for entrepreneurship and innovation on the boundaries of disciplines. All industries are impacted and transformed by the increasing interconnectedness with technological advances in IoT, Big Data, Cloud Computing, Machine Learning and more. This transformation is most apparent in heavily regulated and somewhat slower to change industries like, “Oil and Gas” and “Healthcare”. Any industry that worked in a silo before is likely to leap forward into the new age. These areas are likely to experience most disruptive innovation and are brimming with opportunities for entrepreneurs thinking outside the discipline boundaries.
Oil & Gas industry is on the verge of major transformation. Entrepreneurs with industry specific innovations to enhance operational efficiency and minimize negative environmental impact, will score big. Most recent environmental concerns have been around the impact of fracking or hydraulic fracturing, a process by which water and sand mixture is pumped deep below the earth’s surface, into earth’s dense shale rock formations. Fracking produces many long narrow fractures in the rock formation and helps convert organic matter embedded within the rock to synthetic oil and gas. It has vastly improved oil production. It is estimated that what can be produced by a vertical well in 30 to 35 years, can be done in a horizontal well, in as short a span as 6 months. However, recent studies indicate that fracking has led to an increase in seismic activity. Thus far the activity was minimal but it has now been growing in both strength and number, with increase in fracking. Many Oil and Gas companies have established innovation centers in Silicon Valley to assess and garner technological help to expedite learning about environmental impact and explore if technology might help intervene to minimize negative impact, in addition to enhancing operational efficiency.
Healhcare has also emerged as the most attractive area, pulling in major investment dollars. Internet of things, for instance, will help bring in focus, the prospect of connected health. As increasingly incentives are tied to preventative medicine, providers will look for opportunities for seamless, integrated care. Cloud and big data will enhance the possibility to learn from collective knowledge, access wisdom of the crowd, and enhance quality of health with lesser investment of resources. Big pharmaceutical companies and biotech will look to utilizing technology in bringing therapies to market, with minimal wastage of resources and dollars. Opportunities exist to transform the process of drug development http://bit.ly/1xzpdFx& http://bit.ly/14pkhRO , to digital health advances enabling early identification and treatment of diseases http://bit.ly/11MlM9e , to even better monitoring of medical adherence. While reimbursement is increasingly emerging as a major challenge, insurance providers will look for disruptive, and long term, cost saving innovations.
TiEcon 2015, largest entrepreneurship conference, taking place at Santa Clara Convention Center on May 15 and 16, will feature these new tracks on healthcare http://bit.ly/1OOCV9Z and oil and gas http://bit.ly/1HqQkoc, in addition to featuring companies and speakers making waves in Data Economy, Internet of Things, and Cloud Security tracks.
Register for TiEcon and come and play on the boundaries of disciplines; jump from track to track, network with multi-track participants, angels, VCs, and learn and get inspired. TiEcon will take place at Santa Clara Convention Center, Santa Clara, CA on May 15 and 16. Register through this link https://www.123signup.com/register?id=ygszb&ref=4182698 to get a $100 discount on the two-day conference at the non-member rate. When prompted, enter the promo code VOL500 at checkout.
PS – I am looking to fill a number of full time and contract engineering opportunities in mechanical, quality, software, electrical, firmware engineering in CA & TX. Details are posted in JOBS category at www.darshanavnadkarni.wordpress.com . Some of my full time opportunities are very exciting with a huge potential upside and truly disruptive technology. Resumes can be sent to wd_darshana at hotmail dot com
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship, Biotech - Medical Device - Life Science - Healthcare on April 24, 2015
Healthcare industry is poised to go through impressive transformation, in the coming decade. What some experts have dubbed a 3D transformation, changes in life sciences are happening through massive changes in Diagnostics, Digital Devices, and Data.
Consider this. TiEcon, the largest entrepreneurship conference, focused for several years on computing, storage, hardware, software, firmware, semi conductors, gaming and mobile technologies. HealthTech was not the focus at TiEcon. But HeathTech has recently emerged as one of the hottest areas to invest. Besides offering a special healthcare focused track, on day 2, May 16th, healthtech is integrally woven in most of the other tracks, at TiEcon 2015. Technology has impacted all areas of our lives such that no entrepreneur could look at any industry as a silo. To register go to https://www.123signup.com/register?id=ygszb&ref=4182698 to get a $100 discount on the two-day conference at the non-member rate. When prompted, enter the promo code VOL500 at checkout:
In fact, most of the disruptive innovation is happening on the boundaries of disciplines. This is most pertinent in life science, hospitals and healthcare, healthtech, biotech, pharma, drug development, medtech, digital health, mobile health, wearables space. Every new intersection point between health and an emerging technology, brings its own terminology. Collectively, the aim is to positively transform the quality of lives of healthy and sick people. So how is life science focus woven across several tracks at TiEcon?
John Kapoor, a serial entrepreneur, who is number 577 on Forbes Billionaire List, is going to give a grand keynote address on day 2, Saturday. Kapoor, whose net worth is estimated at $3.5B, has founded and guided two pharmaceutical companies, Insys Therapeutics and Akorn Pharmaceuticals and led them to exceptional success. Pharmaceutical industry is slowly but surely changing to innovate faster, cheaper, more cost efficient process of drug development. Here is link to my recent blog on novel approaches to drug development http://bit.ly/1xzpdFx .
Here is another interesting keynote to watch out for. After helping coin the term, “Data Scientist”, while still in the academia, D. J. Patil did some initial work on deciphering the complexity of the weather patterns and impact of bioweapons proliferation in Central Asia. Here is link to my blog on Patil in 2013 http://bit.ly/YYyOxd . After stints in eBay, PayPal and LinkedIn, Patil was appointed by President Obama, as Chief Data Scientist at the White House. Among other responsibilities, Patil will work on the Administration’s Precision Medicine Initiative, focusing on utilizing advances in data to enable clinicians select most effective treatments. Here IBM’s Watson, an artificial intelligence system with access to millions and millions of pages of structured and unstructured data, to help in efficient diagnosis and suggest possible avenues for treatment, deserves special mention. Here is my link to Dave Farucci’s keynote at TiEcon, several years ago http://bit.ly/JOZmwH .
Besides the keynotes and healthcare representation on panels in other tracks, Day 2 focused Healthcare track panels will address such varied topics as role of “Medical Devices in a Changing Landscape” and “Trials and Tribulations of Adopting Technology in Hospitals”. Eminent speakers include, MD and CEO at Good Samaritan Hospital, Paul Beaupre; Anupam Pathak, Founder & CEO of Lift Labs, acquired by Google X, Brett Knappe, Senior Director of Strategy at Medtronic; Satnam Alag, VP, Software, Illumina; and Darius Naigamwalla, President at Campbell Alliance. Representation from technology rich companies such as IBM, GE, Google X, and Tibco, in discussions on healthcare, along with medtech and big pharma companies like Medtronic, J&J, 23&me, Illumina and Genentech AND representation from healthcare providers like Good Sam, will make for very rich dialogue. Register for TiEcon at https://www.123signup.com/register?id=ygszb&ref=4182698 to get a $100 discount on the two-day conference at the non-member rate. When prompted, enter the promo code VOL500 at checkout:
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship, Biotech - Medical Device - Life Science - Healthcare on March 16, 2015
With Obamacare, the discussion about national health has moved to front and center stage. But what about the status of global health; what are the opportunities and challenges? Just about a decade ago, availability of resources was the biggest problem in the arena of global health. But with the rise in public and private giving, to a large part due to unprecedented giving by Warren Buffet and Bill and Melinda Gates, the challenge has now shifted to better coordination of resources for “equitable, inclusive & sustainable solutions”. According to Council on Foreign Affairs, “for the first time in history, the world is poised to spend enormous resources to conquer the diseases of the poor”.
Kim C. Bush, director of Life Sciences Partnerships at Gates Foundation, is leading the efforts to broaden and deepen the foundation’s engagement and partnership initiatives with various healthcare industry sectors. With an objective to address the critical global health challenges with speed and effectiveness, the foundation is bringing in the industry in this dialog, in a systemic manner. The goal of the Gates foundation is to match global health priorities with the industry capabilities.
Kim Bush will be giving a keynote address at 2015 EPPIC Annual Conference, on March 28th at Santa Clara Convention Center. Entrepreneurs in life science arena, committed to solving some of the major health challenges of our times, may get big insights into where the gaps and the glaring problems are, as well as where the resources are being channeled.
Lineup of speakers on all panels at EPPIcon 2015, is very exciting, with plenty of networking opportunities thrown in. Here is a link to the preview of one of the panels on Digital Health – http://bit.ly/1EQtd5y . No doubt, connected, digital health will also play a prime role in advancing global health. Come and participate in the dialog, network with like minded professionals in Silicon Valley, and hear from key opinion leaders, angel and VC investors and other industry leaders. Early bird registration will expire at midnight today, March, 16. Register today at www.eppicglobal.org .
Also a plug for http://www.healthtechnologyforum.com 2015 annual conference on May 27 and 28 in Burlingame, CA. Early bird pricing will be effective till March, 31. Panels include Innovations for the Underserved, Resilient Communities, Population Health Management, and the conference has a dedicated focus on making a positive difference and transforming health globally. Register soon for an opportunity to hear great speakers and network with professionals committed to making a difference.
EPPIC annual conference is on March, 28 and early bird pricing will end on Monday, March 16. Here is a sneak peek at one of the panels.
Technology is impacting health in interesting ways and many exciting innovations in digital health are expected to change how diseases are tracked, reduce inefficiency in healthcare delivery, reduce costs, improve access to healthcare, increase quality, save resources, and make medicine more personalized. Digital health panel at EPPICon 2015 has diverse and interesting lineup of speakers.
Dr. David Persing, EVP, CMO, and CTO at Cepheid, had made an early resolve to have a positive impact on the world. Guided by intellectual curiosity, while doing his pre-med, he discovered “the power of diagnostics”. The company’s mission at Cepheid is to use the power of molecular diagnostics such that it would enable medical providers to identify and treat diseases early, increasing opportunities to improve patients’ survival and quality of life. Their cloud based platform, “The Digital Miasma” for monitoring of emerging infections earlier, is just launched and is in the implementation phase.
Panelist Deborah Profit is Director of Corporate Projects – Global Clinical & Business Operations for Otsuka Pharmaceutical Development and Commercialization. OPC, is headquartered in Tokyo and is known for popular sports drink Pocari Sweat and energy drink Oronamin C. OPC also developed Abilify, an approved drug treatment for certain mental illnesses, and as of 2013, annual sales of Abilify were over $8 billion a year, making it the highest grossing drug worldwide. You would wonder what has that to do with digital health, until you consider the fact that patient non-compliance is one of the biggest challenges in many illnesses but specifically in mental illnesses. Otsuka has recently made a deal with Proteus Digital Health for tracking medical adherence. Proteus system includes sensor-enabled pills that embed intelligence into the pills so that their ingestion can be precisely tracked. Personally, I am totally against drugs for mental illnesses, many of which do not work as expected; placebo effects are not well identified, clinical studies are often sponsored by drug companies and the list of side effects is daunting and being a psychologist, having seen side effects and heard them being discussed by my colleagues, I have developed absolute disgust for drugs for mental disorders.
Proteus “ingestible sensor” technology however, holds enormous promise for various indications, specifically for treatment and management of chronic conditions. Otsuka plans to make use of Proteus Digital Health’s feedback system in its clinical R&D, presumably for its oncology products.
The next panelist, Dr. Marsha Rose Gillentine is Director of Biotechnology/ Chemical Group at Sterne Kessler Goldstein Fox, LLP and has intimate knowledge and understanding of patent litigation strategy in small molecules, ploymorphs, chemical synthesis, pharmaceutical formulations, methods of treatment, drug delivery devices, animal models, vaccines, polymers and more. Her experience encompasses working with clients to implement lifecycle management strategies, specifically at it relates to personalized medicine patent portfolios.
Jared Heyman is founder and CEO of CrowdMed, a brilliant innovative site that takes connected health to a whole new plane. Often individuals afflicted with rare or neglected diseases, go from doctor to doctor, from pillar to post, just to accurate diagnosis and then they face whole set of new challenges for treatment. CrowdMed is seeking to solve most challenging medical cases, worldwide, with speed and accuracy online, by harnessing the collective wisdom of the crowd.
The Digital Health Panel at EPPICon 2015, will be an exciting panel. Agenda for the entire day looks very interesting and there will be plenty of opportunities for attendees to network and mingle with like-minded professionals. The conference is on Saturday, March 28th at Santa Clara Convention Center, in Santa Clara, CA. Early bird pricing has been extended till March, 16. Please register for the event at the link http://tinyurl.com/o4cj3ow or from www.eppicglobal.org .